Response Biomedical (RPBIF) 10-Q 14 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 01, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	RESPONSE BIOMEDICAL CORP
Trading Symbol	rpbif
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		9,925,256
Amendment Flag	false
Entity Central Index Key	806,888
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - CAD CAD in Thousands		Jun. 30, 2015	Dec. 31, 2014
Current
Cash and cash equivalents		CAD 1,586	CAD 3,221
Trade receivables, net		1,896	702
Other receivables		119	89
Inventories [note 5]		2,725	2,056
Prepaid expenses and other		167	183
Deferred debt financing costs - current portion		66	88
Total current assets		6,559	6,339
Deferred debt financing costs		18	45
Long-term prepaid expenses		93	93
Restricted deposits [note 8]		901	901
Property, plant and equipment		6,151	6,250
Total assets		13,722	13,628
Current
Accounts payable and accrued liabilities [note 6]		5,111	3,867
Term loan - current portion [note 7]		744	494
Lease inducements - current portion [note 8]		169	169
Repayable leasehold improvement allowance - current portion [note 8]	[1]	487	461
Deferred revenue		867	873
Warrant liability [notes 4 and 9]		1,344	1,249
Total current liabilities		8,722	7,113
Lease inducements [note 8]		1,112	1,197
Term loan [note 7]		706	1,004
Repayable leasehold improvement allowance [note 8]		4,958	5,208
		15,498	14,522
Commitments [note 11]		0	0
Shareholders' deficit
Common shares [note 9]		104,314	104,124
Additional paid-in capital [note 9]		15,271	15,241
Deficit		(121,361)	(120,259)
Total shareholders' deficit		(1,776)	(894)
Total liabilities and shareholders' deficit		CAD 13,722	CAD 13,628
[1]	The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three and six month periods ended June 30, 2015 amounted to $114,000 and $224,000 [2014 - $102,000 and $201,000]. Interest payments for the three and six month periods ended June 30, 2015 amounted to $152,000 and $307,000 [2014 - $164,000 and $330,000].

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Income (Loss) (Unaudited) - Scenario, Unspecified [Domain] - CAD shares in Thousands, CAD in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
REVENUE
Product sales [note 12]	CAD 3,563	CAD 3,077	CAD 6,834	CAD 5,636
Collaborative revenue [note 10]	703		972
Total revenue	4,266	3,077	7,806	5,636
Cost of sales [notes 5, 9, and 11]	2,120	1,705	4,296	3,145
Gross profit	2,146	1,372	3,510	2,491
EXPENSES [notes 9 and 11]
Research and development	621	813	1,434	1,624
General and administrative	681	586	1,356	1,397
Sales and marketing	469	483	1,133	1,129
Total operating expenses	1,771	1,882	3,923	4,150
OTHER EXPENSES (INCOME)
Interest expense and amortization of deferred financing costs and debt discount [note 7]	225	226	460	423
Interest income	(2)	(4)	(5)	(9)
Other (income)/expense	(17)	15	5	32
Foreign exchange loss	21	4	134	8
Unrealized loss (gain) on revaluation of warrant liability [note 4]	150	(1,039)	95	(878)
Total other expenses (income)	377	(798)	689	(424)
Net income (loss) and comprehensive income (loss) for the period	CAD (2)	CAD 288	CAD (1,102)	CAD (1,235)
Earnings (loss) per common share - basic [note 9] (in Dollars per share)	CAD 0	CAD 0.04	CAD (0.11)	CAD (0.16)
Earnings (loss) per common share - diluted [note 9] (in Dollars per share)	CAD 0	CAD 0.04	CAD (0.11)	CAD (0.16)
Weighted average number of common shares outstanding - basic [note 9] (in Shares)	9,889,028	7,944,235	9,832,274	7,912,580
Weighted average number of common shares outstanding - diluted [note 9] (in Shares)	9,889,028	8,023,175	9,832,274	7,912,580

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Deficit (Unaudited) - CAD CAD in Thousands	Common Stock [Member]Private Placement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Private Placement [Member]	Total
Balance at Dec. 31, 2013		CAD 101,945	CAD 14,742	CAD (118,169)		CAD (1,482)
Balance (in Shares) at Dec. 31, 2013		7,870,925
Net loss				(2,090)		(2,090)
Private placement, net of issue costs	CAD 2,024				CAD 2,024
Private placement, net of issue costs (in Shares)	1,800,000
Net shares issued upon conversion of restricted share units		CAD 155	(155)
Net shares issued upon conversion of restricted share units (in Shares)		88,635
Net warrants issued per terms of loan			113			113
Stock-based compensation expense			381			381
Restricted share units			160			160
Balance at Dec. 31, 2014		CAD 104,124	15,241	(120,259)		(894)
Balance (in Shares) at Dec. 31, 2014		9,759,560
Net loss				(1,102)		(1,102)
Net shares issued upon conversion of restricted share units		CAD 190	(190)
Net shares issued upon conversion of restricted share units (in Shares)		165,696
Stock-based compensation expense			105			105
Restricted share units			115			115
Balance at Jun. 30, 2015		CAD 104,314	CAD 15,271	CAD (121,361)		CAD (1,776)
Balance (in Shares) at Jun. 30, 2015		9,925,256

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - CAD	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Net loss for the period	CAD (1,102,000)	CAD (1,235,000)
Add (deduct) items not involving cash:
Depreciation of property, plant and equipment	505,000	491,000
Amortization of deferred lease inducements	(85,000)	(86,000)
Amortization of deferred financing costs	49,000	42,000
Amortization of discount on debt	29,000	14,000
Stock-based compensation	105,000	233,000
Unrealized loss (gain) on revaluation of warrant liability	95,000	(878,000)
Other non-cash items	118,000	(60,000)
Changes in non-cash working capital:
Trade receivables	(1,194,000)	166,000
Other receivables	(30,000)	77,000
Inventories	(669,000)	(324,000)
Prepaid expenses and other	16,000	(31,000)
Accounts payable and accrued liabilities	1,306,000	51,000
Deferred revenue	(6,000)	14,000
Cash used in operating activities	(863,000)	(1,526,000)
INVESTING ACTIVITIES
Purchase of property, plant and equipment	(353,000)	(145,000)
Cash used in investing activities	(353,000)	(145,000)
FINANCING ACTIVITIES
Repayment of repayable leasehold improvement allowance	(224,000)	(201,000)
Repayment of term loan	(195,000)	0
Proceeds from term loan	0	1,661,000
Debt financing cost	0	(136,000)
Cash provided by (used in) financing activities	(419,000)	1,324,000
Decrease in cash and cash equivalents during the period	(1,635,000)	(347,000)
Cash and cash equivalents, beginning of period	3,221,000	2,958,000
Cash and cash equivalents, end of period	CAD 1,586,000	CAD 2,611,000

Note 1 - Description of Busines

Note 1 - Description of Business	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block [Abstract]
Business Description and Basis of Presentation [Text Block]	1. DESCRIPTION OF BUSINESS Response Biomedical Corp. (“Response” or the “Company”) was incorporated on August 20, 1980 under the predecessor to the Business Corporations Act (British Columbia). The Company’s wholly owned US subsidiary, Response Point of Care Inc., was incorporated on November 9, 2012 in the State of Delaware. The Company is engaged in the research, development, commercialization and distribution of diagnostic technologies for the medical point of care (POC), laboratory and on-site environmental testing markets. POC and on-site diagnostic tests (or assays) are simple, non-laboratory based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges and/or dipsticks. Since 1996, the Company has developed and commercialized a proprietary diagnostic system called RAMP ® The RAMP ® ® ®

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Going Concern Uncertainty	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	2. BASIS OF PRESENTATION AND GOING CONCERN UNCERTAINTY These unaudited interim consolidated financial statements have been prepared by management in Canadian dollars in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required to be presented for complete financial statements. The accompanying unaudited consolidated financial statements reflect, in the opinion of management, all adjustments (which include reclassifications and normal recurring adjustments) necessary for a fair presentation of the results for the interim periods presented. The accompanying consolidated balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year then ended. The consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2014 and filed with the United States Securities and Exchange Commission (“SEC”) on March 19, 2015. Going Concern Uncertainty The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. During the six month period ended June 30, 2015, the Company has incurred a net loss of $1.1 million and negative cash flows from operations of $863,000. As of June 30, 2015, the Company had a cash balance of $1.6 million, an accumulated deficit of $121.4 million, a shareholders’ deficit of $1.8 million, and a negative working capital balance of $2.2 million. In addition, the Company has various operating leases and purchase commitments for inventory (refer to note 11). Included in current liabilities is a warrant liability in the amount of $1.3 million that is required to be measured at fair value. The potential settlement of these warrants would not have a cash impact as they may only be exercised on a net cashless basis. Without taking into account the warrant liability mentioned above, current liabilities exceed current assets by $819,000. During the six month period ended June 30, 2015, the Company’s national distributor in China, appointed by the Company early this year, met its contractual minimums for purchases of products from the Company. Sales to this distributor represented approximately 70% of product sales in the first half of this year. However, the national distributor recently indicated that it has built up inventory at a higher rate than its current sales to end-users. The national distributor may have sufficient inventory to support its expected sales in the short term and consequently, may make significantly lower, or possibly no, purchases from the Company during the third quarter of 2015. No returns of the products purchased by the national distributor are either expected or permitted under the terms of its distribution agreement. As a result, in order to address the resulting expected sharp, temporary decline in our shipments to this China distributor and thus a projected decline in total product sales in the third quarter, the Company has implemented several cash conservation and cost reduction initiatives to extend its available cash resources. In addition, the Company is also seeking additional financing alternatives. While the Company is pursuing these various initiatives, there is no assurance that these efforts will be sufficient to fund the Company’s operations or that the downturn in sales will be temporary. The ability of the Company to continue as a going concern is uncertain and dependent on the Company’s ability to obtain additional financing and/or achieve cash flow positive operations. Management has, thus far, financed the operations through a series of equity financings, debt financing, and collaborative arrangements. On October 15, 2014, the Company entered into a funded Technology Development Agreement and on February 16, 2015, a Collaboration Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. (“Joinstar”) to support the co-development by Response and Joinstar of components and multiple assays that will run on a high throughput rapid immunoassay analyzer developed by Joinstar. Under the terms of the agreements, Response has received milestones totaling US$1.64 million to date and is eligible to receive a further US$2.16 million in development milestones over the remaining planned nine month project period. In conjunction with the signing of the Collaborative Agreement, Response and Joinstar entered into a definitive Supply Agreement whereby Response will provide certain materials required for Joinstar to manufacture and sell the developed assays specifically to run on their analyzer. Under the terms of the Supply Agreement, Response is eligible to receive a guaranteed US$1.78 million in revenue-based payments over the first five years of commercialization of the co-developed assays. In addition to the Joinstar agreements, on February 11, 2014, the Company secured a US$2.5 million term loan from Silicon Valley Bank (“SVB”) of which only US$1.5 million was drawn down. On December 15, 2014, Response announced that it had entered into an amendment to the original term loan agreement with SVB. Under the amendment, SVB agreed to continue to advance the remaining outstanding principal of US$1.4 million for the same term and interest rate, waive its rights in respect of previous breaches of certain financial covenants and to remove any future minimum revenue and liquidity ratio financial covenants. In addition, SVB received additional warrants and will receive a final payment of up to 4% of the principal advanced. Refer to note 7 for the significant terms to the loan. Management believes that, with a combination of some or all of the various cost reduction, cash conservation, sales and marketing, and, if necessary, financing initiatives, and with the targeted execution under the Joinstar Agreements, based on the current level of operations and excluding out of the ordinary cash management measures, the Company’s cash and cash equivalent balances, including cash generated from operations, will be sufficient to meet the anticipated cash requirements through the next twelve months. However, due to the Company’s history of losses, there is substantial doubt over the Company’s ability to continue as a going concern as it is dependent on meeting the development milestones required to earn the additional US$2.16 million in development fees under the Collaboration Agreement with Joinstar , achieving profitable operations, or obtaining additional financing, the outcomes of which cannot be predicted at this time. The consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Note 3 - Recent Accounting Pron

Note 3 - Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	3. RECENT ACCOUNTING PRONOUNCEMENTS Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-09, "Revenue from Contracts with Customers", which will supersede most of the existing revenue recognition guidance under U.S. GAAP. This ASU requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This pronouncement is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted. The ASU allows for either full retrospective or modified retrospective adoption. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 2015-40) (“ASU 2014-15”). ASU 2014-15 provides guidance to U.S. GAAP about management’s responsibility to evaluate whether there is a substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. This new rule requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles currently in the U.S. auditing standards. Specifically, ASU 2014-15 (1) defines the term substantial doubt, (2) requires an evaluation of every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires an express statement and other disclosures when substantial doubt is not alleviated, and (5) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This guidance is effective for annual periods ending after December 15, 2016 . In April 2015, the FASB issued ASU 2015-03, Interest-Imputation of Interest (Subtopic 835-30) (“ASU 2015-03”). ASU 2015-03 was issued to simplify the presentation of debt issuance costs. The guidance requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by these amendments. This guidance should be applied on a retrospective basis, wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. The guidance will be effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted for financial statements that have not been previously issued. We are currently evaluating the impact, if any, of the adoption of this newly issued guidance to our consolidated financial statements.

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	4. FAIR VALUE MEASUREMENTS Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (“exit price”) in an orderly transaction between market participants at the measurement date. Fair value measurements of financial instruments are determined by using a fair value hierarchy that prioritizes the inputs to valuation techniques into three levels according to the relative reliability of the inputs used to estimate the fair values. The three levels of inputs used to measure fair value are as follows: Level 1 – Unadjusted quoted prices in active markets for identical financial instruments; Level 2 – Inputs other than quoted prices that are observable for the financial instrument either directly or indirectly; and Level 3 – Inputs that are not based on observable market data. In determining fair value measurements, the Company uses the most observable inputs when available. For certain of the Company’s financial instruments, including cash and cash equivalents, trade receivables, other receivables, and accounts payable and accrued liabilities the carrying amounts approximate fair values due to their short-term nature. The carrying value of the restricted deposits approximates its fair value due to the nature of the cash deposit. The fair value of the term loan approximates its carrying value as the term loan with SVB was secured during the first quarter of 2014 and renegotiated in the fourth quarter of 2014 and therefore approximates the current market rate for the term loan. The fair value of the repayable leasehold improvement allowance approximates its carrying value as the fixed interest rate of 11% is considered to approximate the current market rate. The fair value hierarchy level at which a financial instrument is categorized is determined on the basis of the lowest level input that is significant to the fair value measurement (in thousands): Financial Instrument s carried at fair value as of June 30 , 2015 Level 1 Level 2 Level 3 Total Liabilities $ $ $ $ Warrant Liability - - 1,344 1,344 As of June 30, 2015, the warrant liability is recorded at its fair value of $1.3 million. The Company reassesses the fair value of the common stock warrants at each reporting date utilizing a Black-Scholes pricing model. Inputs used in the pricing model include estimates of stock price volatility, contractual term of the warrant, and risk-free interest rate (refer to note 9[g]). The computation of expected volatility was based on the historical volatility of the Company’s stock. A small change in the estimates used in the Black-Scholes pricing model may have a relatively large change in the estimated valuation of the common stock warrants. The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the six month period ended June 30, 2015 (in thousands): Balance at December 31, 2014 Unrealized loss Exercise of Warrants Balance at June 30 , 2015 Warrant Liability 1,249 95 - 1,344 Quantitative information about unobservable inputs used in Level 3 fair value measurements is presented below: Valuation Technique Unobservable Input As at June 30, 2015 As at December 31 , 2014 Warrant Liability Option Model Stock Price Volatility 100 % 106 % A 5% increase or decrease in stock price volatility would cause an approximate corresponding $90,000 increase or decrease to the Warrant Liability ($82,000 – December 31, 2014).

Note 5 - Inventories

Note 5 - Inventories	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	5. INVENTORIES Inventories are comprised of the following (in thousands): June 30, 2015 December 31, 2014 $ $ Raw materials 1,426 1,212 Work in progress 742 309 Finished goods 557 535 2,725 2,056 The carrying value of inventory as of June 30, 2015 includes a write-down and a provision for expired, obsolete, and damaged inventory in the amount of $95,000 [December 31, 2014 - $135,000]. For the three and six month period ended June 30, 2015, inventory write-downs and obsolescence charges were $47,000 and $128,000 [2014 - $57 ,000 and $122,000].

Note 6 - Accounts Payable and A

Note 6 - Accounts Payable and Accrued Liabilities	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts payable and accrued liabilities comprise (in thousands): June 30, 2015 December 31, 2014 $ $ Trade accounts payable 2,187 1,624 Employee related accounts payable and accrued liabilities 1,221 1,307 Royalties 287 287 Other accrued liabilities 1,416 649 5,111 3,867 Accounts payable and accrued liabilities include $68,000 of additions to property, plant, and equipment as at June 30, 2015. This amount has been excluded from cash used in investing activities on the consolidated statements of cash flows for the six months ended June 30, 2015 as the cash had not been disbursed. Consequently, it has also been excluded from cash used in operating activities.

Note 7 - Term Loan

Note 7 - Term Loan	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block [Abstract]
Long-term Debt [Text Block]	7. TERM LOAN On February 11, 2014, the Company entered into a loan and security agreement with SVB providing for up to a US$2.5 million term loan. The loan is secured by substantially all of the assets of the Company. The loan included financial covenants that were later removed in an amendment (refer to discussion below). The loan also includes certain non-financial covenants as well as a subjective acceleration clause. Under the terms of the original loan agreement, the loan bears an interest rate of Wall Street Journal Prime Rate plus 2.5% annually. Interest only payments were made until October 1, 2014 at which time, 32 equal monthly installments of principal plus accrued interest started to be made. On December 15, 2014, the Company entered into an amendment to the original loan agreement with SVB. Under the amendment, SVB agreed to continue to advance the remaining outstanding principal of US$1.4 million for the same term and interest rate under the original agreement. In addition, SVB waived its rights in respect of certain breaches and removed any future financial covenants. Interest only payments were made until April 1, 2015, at which time, 26 equal monthly installments of principal plus accrued interest are being made through to maturity on May 1, 2017. In addition, the Company will pay an additional final payment of up to 4% of the outstanding principal advanced upon repayment. The loan contains a voluntary prepayment option whereby the principal amount can be prepaid in whole, or in part, for a fixed fee if a prepayment is made on or before February 10, 2016. In connection with the original loan and amendment discussed above, 107,701 warrants with exercise prices ranging from $1.00 to $1.831 per warrant and a term of 10 years were granted to SVB. These warrants were measured at their fair market value using the Black-Scholes model on the date of their grants and had a combined estimated fair market value of $113,000 which was recorded as a debt discount that is being amortized into income over the term of the loan using the effective interest method. In addition, there were $233,000 of fees related to the term loan that are also being amortized over the term of the loan using the effective interest method. Amortization of the deferred financing costs for the three and six month periods ended June 30, 2015 were $24,000 and $50,000 (2014 – $29,000 and $42,000) and amortization of the debt discount for the three and six month periods ended June 30, 2015 was $14,000 and $29,000 (2014 – $9,000 and $14,000). Both of these amounts are included in interest expense and amortization of deferred financing costs and debt discount on the consolidated statements of income (loss) and comprehensive income (loss). The term loan is comprised of the following amounts (in thousands): June 30, 2015 December 31, 2014 $ $ Current portion of term loan 783 546 Current portion of unamortized debt discount (39 ) (52 ) Current portion of long-term debt, net debt discount 744 494 Long-term portion of term loan 717 1,031 Long-term portion of unamortized debt discount (11 ) (27 ) Long-term of long-term debt, net debt discount 706 1,004 Total 1,450 1,498 Future principal payments for the term loan as of June 30, 2015, are as follows (in thousands): June 30, $ 2016 783 2017 717 Total 1,500

Note 8 - Lease Inducements

Note 8 - Lease Inducements	6 Months Ended
	Jun. 30, 2015
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Liabilities Disclosure [Text Block]	8. LEASE INDUCEMENTS Lease agreements entered into by the Company for its offices provides for lease inducements to be provided by the landlord to the Company, which are summarized as follows (in thousands): June 30, 2015 December 31, 2014 $ $ Current Portion Rent-free inducement [i] 55 54 Non-repayable leasehold improvement allowance [ii] 114 115 169 169 Repayable leasehold improvement allowance [iii] 487 461 Total Current Portion 656 630 Long-Term Portion Rent-free inducement [i] 357 385 Non-repayable leasehold improvement allowance [ii] 755 812 1,112 1,197 Repayable leasehold improvement allowance [iii] 4,958 5,208 Total Long-Term Portion 6,070 6,405 Total 6,726 7,035 The lease inducements disclosed on the consolidated balance sheets as a result of these benefits is comprised of the following: [i] In 2007, the Company entered into a long-term facility lease agreement that included an eight and one half month rent-free period from May 17, 2007 to February 1, 2008. The lease inducement benefit arising from the rent-free period is being amortized on a straight-line basis over the term of the operating lease as a reduction to rental expense. Amortization expense for the three and six month periods ended June 30, 2015 amounted to $13,000 and $27,000 [2014 - $13,000 and $27,000]. [ii] The Company received a non-repayable allowance for an amount of $1.7 million for expenditures related to general upgrades to the facility. The lease inducement benefit arising from the non-repayable leasehold improvement allowance is being amortized on a straight-line basis over the balance of the term of the lease beginning April 1, 2008 as a reduction to rental expense. Amortization expense for the three and six month periods ended June 30, 2015 amounted to $29,000 and $58,000 [2014 - $28,000 and $57,000]. [iii] The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three and six month periods ended June 30, 2015 amounted to $114,000 and $224,000 [2014 - $102,000 and $201,000]. Interest payments for the three and six month periods ended June 30, 2015 amounted to $152,000 and $307,000 [2014 - $164,000 and $330,000]. To secure the lease, the Company is maintaining a security deposit with the landlord in the form of an irrevocable letter of credit in the amount of $871,000 collateralized by a term deposit with a market value of $871,000 that is presented as part of restricted deposits in the long-term asset section of the balance sheets.

Note 9 - Share Capital and Addi

Note 9 - Share Capital and Additional Paid-in Capital	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9 . SHARE CAPITAL AND ADDITIONAL PAID-IN CAPITAL [a] Authorized - Unlimited common shares without par value. [b] Issued 2014 Private Placement On December 12, 2014, the Company closed a private placement with Joinstar related entities consisting of 1,800,000 common shares at a price of $1.21 per share for total gross proceeds of $2,178,000. The net proceeds were $2,024,000 after deduction of $154,000 of financing costs. [c] Stock option plan At the Annual General Meeting held September 3, 2008, the Company’s shareholders approved a stock option plan (“2008 Plan”). Under the plan, the Company may grant options to purchase common shares in the Company to employees, directors, officers and consultants of the Company. The exercise price of the options is determined by the Board to be equal to the fair market value of the commons shares on the grant date. The Company estimates the fair value of options on the date of the grant. The options vest over the requisite service period in accordance with terms as determined by the Board, typically over four years. Stock options expire no later than ten years from the date of grant. At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders’ approved a change to the Company’s 2008 stock option plan permitting the maximum shares authorized to be issued under the plan to be up to 20% of the issued and outstanding common shares outstanding at any point in time. Of the 1,985,051 stock options authorized for grant under the 2008 Plan as at June 30, 2015, options for 1,333,835 shares were outstanding and 651,216 stock options were available for future grant. The following assumptions were used to estimate the fair value of options granted during the six month period ended June 30, 2015, and 2014 using a Black-Scholes option-pricing model: Six Months Ended June 30, 2015 2014 Risk-free interest rates 1.31 % 2.05 % Expected dividend yield 0 % 0 % Expected life (in years) 5.78 5.86 Expected volatility 121 % 126 % Fair value per stock option $ 0.67 $ 1.31 The expected volatility reflects the assumption that the historical volatility of common stock of the Company over a period similar to the expected life of the options is indicative of future trends. The Company estimates the risk-free interest rate using the Bank of Canada bond yield with a remaining term equal to the expected life of the option. The Company uses the simplified method for estimating the stock option term for stock option grants during the six month period ended June 30, 2015 as the Company has determined that the stock options are “plain vanilla” and historical share option exercises do not apply as the vesting term and contractual lives have significantly changed from those stock options exercised previously. At June 30, 2015, the following stock options were outstanding: Range of Number of shares under option Weighted average remaining contractual life Weighted average exercise price Number of options currently exercisable Weighted average exercise price $ # (years) $ # $ 0.72 - 0.92 519,433 9.78 0.79 - - 1.02 - 1.60 259,592 8.03 1.48 160,388 1.45 2.20 386,361 6.79 2.20 361,414 2.20 3.00 - 3.10 166,625 7.72 3.09 154,422 3.10 6.80 - 8.20 1,824 0.62 7.70 1,824 7.70 0.72 - 8.20 1,333,835 8.30 1.63 678,048 2.24 The options expire at various dates from December 1, 2015 to May 19, 2025. Stock option transactions and the number of stock options outstanding are summarized below: Number of optioned Weighted average common shares exercise price # $ Balance, December 31, 2014 1,007,629 1.99 Options granted 449,743 0.78 Options forfeited (123,537 ) 1.47 Balance, June 30, 2015 1,333,835 1.63 [d] Restricted share unit plan At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders approved a new restricted share unit plan (“RSU Plan”). Under the plan, the Company may grant Restricted Share Units (“RSUs”) to employees, directors, and eligible consultants which entitle each participant to either one common share of the Company on a time vested basis or a cash payout equal to the number of vested RSUs multiplied by the then current market value of the RSUs. The fair market value of the RSUs is determined based upon the number of RSUs granted and the quoted closing price of the Company’s stock on the trading day immediately preceding the date of determination. The duration of the vesting period and other vesting terms applicable to the grant of the RSUs shall be determined by the Board. Number Weighted average of RSUs exercise price # $ Balance, December 31, 2014 136,348 1.39 RSUs granted 141,837 0.81 RSUs converted to common shares (165,696 ) (1.15 ) Balance, June 30, 2015 112,489 1.02 The restricted share units that were granted during the six month period ended June 30, 2015 were to settle a director compensation liability that was recorded in accounts payable and accrued liabilities. The $115,000 liability has been excluded from the change in accounts payable and accrued liabilities on the consolidated statement of cash flows. Of the 248,131 RSUs authorized for grant under the RSU Plan as at June 30, 2015, 135,642 RSUs are available for grant. [e] Deferred share unit plan At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders approved a new non-employee director deferred share unit plan (“DSU Plan”). A Deferred Share Unit (“DSU”) is a right granted to non-employee directors which entitle each participant to either one common share of the Company on a time vested basis or a cash payout equal to the number of DSUs multiplied by the then current market value of the DSUs. The fair market value of the DSU’s is determined based upon the number of DSUs granted and the quoted price of the Company’s stock on the trading day immediately preceding the determination date. The duration of the vesting period and other vesting terms applicable to the grant of the DSU’s shall be determined by the Board. Of the 248,131 DSUs authorized for grant under the DSU Plan as at June 30, 2015, all are available for grant. [f] Stock-based compensation The following table shows stock-based compensation allocated by type of cost (in thousands): Three Months Ended Six Months Ended 2015 2014 2015 2014 $ $ $ $ Cost of sales 9 9 17 18 Research and development 11 11 22 23 General and administrative 27 50 50 169 Sales and marketing 3 12 16 23 50 82 105 233 As of June 30, 2015, the total unrecognized compensation related to stock options granted amounts to $634,000, which is expected to be recognized over a weighted average service period of 2.37 years. [g] Common share purchase warrants At June 30, 2015, there were 86,865,691 warrants outstanding to purchase shares of common stock, with expiry dates ranging from November 7, 2015 to December 15, 2024. Of the total 86,865,691 warrants outstanding, 86,103,744 warrants (the warrants related to the 2011 financing) entitle the holder thereof to purchase 1/20 th There have been no common share purchase warrant transactions during the six months ended June 30, 2015. The estimated fair value of the warrants related to the 2011 financing is reassessed at each balance sheet date using the Black-Scholes option pricing model. The following assumptions were used to value the warrants on the following balance sheet dates: As at June 30, 2015 2014 Risk-free interest rates 0.49 % 1.09 % Expected dividend yield 0 % 0 % Expected life (in years) 1.5 2.5 Expected volatility 100 % 124 % Fair value of warrant $ 0.0156 $ 0.0508 [h] Earnings per common share The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted earnings (loss) per share (in thousands, except share and per share data): Three Months Ended Six Months Ended 2015 2014 2015 2014 $ $ $ $ Numerator: Net income (loss) available to common shareholders $ (2 ) $ 288 $ (1,102 ) $ (1,235 ) Denominator: Weighted average number of common shares outstanding - basic 9,889,028 7,944,235 9,832,274 7,912,580 Weighted average effect of dilutive securities: RSUs - 72,896 - - Stock options - 6,044 - - Weighted average number of common shares outstanding - diluted 9,889,028 8,023,175 9,832,274 7,912,580 Basic net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding using the treasury stock method. Dilutive potential common shares outstanding include outstanding warrants, stock options, and restricted share units. 86,865,691 warrants, 1,333,835 stock options and 112,489 restricted share units have been excluded from the computation of diluted earnings per share for the three month period ended June 30, 2015 as the Company has incurred a net loss during the period and their inclusion would be anti-dilutive to the loss per share (2014 – 86,810,786 warrants and 1,422,632 stock options were excluded). 86,865,691 warrants, 1,333,835 stock options and 112,489 restricted share units have been excluded from the computation of diluted earnings per share for the six month period ended June 30, 2015 as the Company has incurred a net loss during the period and their inclusion would be anti-dilutive to the loss per share (2014 – 86,810,786 warrants, 1,455,362 stock options, and 72,896 RSUs were excluded).

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	10. RELATED PARTY TRANSACTIONS The Company received US$1.28 million from Joinstar upon signing of the Technology Development Agreement and Collaboration Agreement. These upfront payments are being recognized into income over the expected development period and for the three and six month periods ended June 30, 2015, $246,000 and $515,000 was recognized (2014 – nil). These development fees are included under collaborative revenue in the consolidated statements of income (loss) and comprehensive income (loss). The unrecognized portion of the development fees are included under deferred revenue on the consolidated balance sheet. In addition, the Company received US $360,000 upon achieving the third milestone under the Collaboration Agreement with Joinstar during the three month period ended June 30, 2015. For the three and six month periods ended June 30, 2015, $457,000 (2014 – nil) was included under collaborative revenue in the consolidated statements of income (loss) and comprehensive income (loss).

Note 11 - Commitments

Note 11 - Commitments	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block Supplement [Abstract]
Commitments Disclosure [Text Block]	11. COMMITMENTS [a] License agreements The Company entered into a non-exclusive license agreement, effective July 2005, as amended June 2008, to use and sublicense certain technology (“Technology”) for one of the Company’s cardiac tests. In consideration for these rights, the Company paid a non-refundable license issuance fee of $2.0 million in the first two years after execution of the agreement and is required to pay quarterly royalties on the sale of products that incorporate the Technology. For the three and six month periods ended June 30, 2015, the Company incurred an expense of $248,000 and $465,000 [2014 - $157,000 and $274,000] for royalties. Royalty and license fees incurred are included in cost of sales. [b] Supply agreement The Company entered into a supply agreement, effective September 2003 for certain reagents for the Company’s RAMP ® ® [c] Lease agreements [i] The Company entered into a long-term agreement to lease a single tenant 46,000 square foot facility to house all of the Company’s operations. Rent is payable from February 1, 2008 to January 31, 2023. The Company is required to pay the landlord total gross monthly payments of approximately $173,000, which is comprised of base rent, administrative and management fees, estimated property taxes and repayments of the repayable leasehold improvement allowance [note 8[iii]]. [ii] The Company entered into a lease agreement for office space for our Shanghai representative office that expires on September 9, 2015. The lease agreement has been extended to December 9, 2015. The Company is required to make monthly payments of approximately $8,000 for base rent and management fees under the lease agreement. [iii] The Company has entered into operating leases for administrative equipment. For the three and six month periods ended June 30, 2015, $211,000 and $406,000 [2014 - $203,000 and $389,000] was incurred for expenses related to base rent, administrative and management fees and estimated property taxes offset by amortization of both the rent-free inducement [note 8[i]] and non-repayable leasehold improvement allowance [note 8[ii]]. These expenses are allocated to cost of sales, research and development, general and administrative, and sales and marketing expenses. [d] Purchase Commitments As at June 30, 2015, the Company has outstanding purchase commitments of $3.0 million to purchase inventory and capital equipment over the next five years of which $2.0 million will be completed during the remaining six months of 2015. [e ] Indemnification of directors and officers Under the Articles of the Company, applicable law and agreements with its directors and officers, the Company, in circumstances where the individual has acted legally, honestly and in good faith, may, or is required to indemnify its directors and officers against certain losses. The Company's liability in respect of the indemnities is not limited. The maximum potential of the future payments is unlimited. However, the Company maintains appropriate liability insurance that limits the exposure and enables the Company to recover any future amounts paid, less any deductible amounts pursuant to the terms of the respective policies, the amounts of which are not considered material. [f] Indemnification of third parties The Company has entered into license and research agreements with third parties that include indemnification provisions that are customary in the industry. These indemnifications generally require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims for damages arising from these transactions. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount that it could be required to pay. To date, the Company has not made any indemnification payments under such agreements and no amount has been accrued in these consolidated financial statements with respect to these indemnification obligations.

Note 12 - Segmented Information

Note 12 - Segmented Information	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	12. SEGMENTED INFORMATION The Company operates primarily in one business segment, the research, development, commercialization and distribution of diagnostic technologies, with primarily all of its assets and operations located in Canada. The Company’s revenues are generated from product sales primarily in Asia, the United States, and Europe. Expenses are primarily incurred from purchases made from suppliers in Canada and the United States. Customers that represent a concentration risk are those whose outstanding receivable is 10% or greater than the total balance or those customers who represent 10% or greater of our total revenue. For the three month period ended June 30, 2015, $2.5 (70%) in product sales was generated from one customer [2014 - $2.2 million (72%) from four customers of which one customer represented 23%, two customers each represented 19%, and the other customer 11%]. For the six month period ended June 30, 2015, $4.8 million (71%) in product sales was generated from one customer [2014 - $4.0 million (71%) from four customers of which one customer represented 29%, one customer represented 21%, one customer represented 11%, and the other customer 10%]. Product sales by customer location were as follows (in thousands): Three Months Ended Six Months Ended 2015 2014 2015 2014 $ $ $ $ China 2,545 1,882 4,923 3,407 United States 432 521 686 731 Europe 204 284 404 712 Asia (excluding China) 127 127 279 282 Canada 17 6 24 10 Other 238 257 518 494 Total 3,563 3,077 6,834 5,636 Product sales by type of product were as follows (in thousands): Three Months Ended Six Months Ended 2015 2014 2015 2014 $ $ $ $ Cardiovascular 3,143 2,609 6,232 5,047 Infectious Diseases 1 3 50 72 Biodefense products 144 131 199 175 West Nile Virus (Environmental) 275 334 353 342 Total 3,563 3,077 6,834 5,636

Note 13 - Comparative Figures

Note 13 - Comparative Figures	6 Months Ended
	Jun. 30, 2015
Comparative Figures [Abstract]
Comparative Figures [Text Block]	13. COMPARATIVE FIGURES Certain comparative figures have been reclassified from the amounts previously reported to confirm to the presentation adopted in the current year. Taxes paid in China for the representative office previously presented as income taxes have been retroactively reclassified as other expenses.

Note 4 - Fair Value Measureme19

Note 4 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value, by Balance Sheet Grouping [Table Text Block]	Level 1 Level 2 Level 3 Total Liabilities $ $ $ $ Warrant Liability - - 1,344 1,344
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Balance at December 31, 2014 Unrealized loss Exercise of Warrants Balance at June 30 , 2015 Warrant Liability 1,249 95 - 1,344
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	Valuation Technique Unobservable Input As at June 30, 2015 As at December 31 , 2014 Warrant Liability Option Model Stock Price Volatility 100 % 106 %

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	June 30, 2015 December 31, 2014 $ $ Raw materials 1,426 1,212 Work in progress 742 309 Finished goods 557 535 2,725 2,056

Note 6 - Accounts Payable and21

Note 6 - Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	June 30, 2015 December 31, 2014 $ $ Trade accounts payable 2,187 1,624 Employee related accounts payable and accrued liabilities 1,221 1,307 Royalties 287 287 Other accrued liabilities 1,416 649 5,111 3,867

Note 7 - Term Loan (Tables)

Note 7 - Term Loan (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	June 30, 2015 December 31, 2014 $ $ Current portion of term loan 783 546 Current portion of unamortized debt discount (39 ) (52 ) Current portion of long-term debt, net debt discount 744 494 Long-term portion of term loan 717 1,031 Long-term portion of unamortized debt discount (11 ) (27 ) Long-term of long-term debt, net debt discount 706 1,004 Total 1,450 1,498
Schedule of Maturities of Long-term Debt [Table Text Block]	June 30, $ 2016 783 2017 717 Total 1,500

Note 8 - Lease Inducements (Tab

Note 8 - Lease Inducements (Tables)	6 Months Ended
	Jun. 30, 2015
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Lease Inducements [Table Text Block]	June 30, 2015 December 31, 2014 $ $ Current Portion Rent-free inducement [i] 55 54 Non-repayable leasehold improvement allowance [ii] 114 115 169 169 Repayable leasehold improvement allowance [iii] 487 461 Total Current Portion 656 630 Long-Term Portion Rent-free inducement [i] 357 385 Non-repayable leasehold improvement allowance [ii] 755 812 1,112 1,197 Repayable leasehold improvement allowance [iii] 4,958 5,208 Total Long-Term Portion 6,070 6,405 Total 6,726 7,035

Note 9 - Share Capital and Ad24

Note 9 - Share Capital and Additional Paid-in Capital (Tables)	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Six Months Ended June 30, 2015 2014 Risk-free interest rates 1.31 % 2.05 % Expected dividend yield 0 % 0 % Expected life (in years) 5.78 5.86 Expected volatility 121 % 126 % Fair value per stock option $ 0.67 $ 1.31
Schedule of Share-based Compensation, Activity [Table Text Block]	Range of Number of shares under option Weighted average remaining contractual life Weighted average exercise price Number of options currently exercisable Weighted average exercise price $ # (years) $ # $ 0.72 - 0.92 519,433 9.78 0.79 - - 1.02 - 1.60 259,592 8.03 1.48 160,388 1.45 2.20 386,361 6.79 2.20 361,414 2.20 3.00 - 3.10 166,625 7.72 3.09 154,422 3.10 6.80 - 8.20 1,824 0.62 7.70 1,824 7.70 0.72 - 8.20 1,333,835 8.30 1.63 678,048 2.24
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of optioned Weighted average common shares exercise price # $ Balance, December 31, 2014 1,007,629 1.99 Options granted 449,743 0.78 Options forfeited (123,537 ) 1.47 Balance, June 30, 2015 1,333,835 1.63
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	Number Weighted average of RSUs exercise price # $ Balance, December 31, 2014 136,348 1.39 RSUs granted 141,837 0.81 RSUs converted to common shares (165,696 ) (1.15 ) Balance, June 30, 2015 112,489 1.02
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended Six Months Ended 2015 2014 2015 2014 $ $ $ $ Cost of sales 9 9 17 18 Research and development 11 11 22 23 General and administrative 27 50 50 169 Sales and marketing 3 12 16 23 50 82 105 233
Estimated Fair Value of Warrants Issued, Valuation Assumptions [Table Text Block]	As at June 30, 2015 2014 Risk-free interest rates 0.49 % 1.09 % Expected dividend yield 0 % 0 % Expected life (in years) 1.5 2.5 Expected volatility 100 % 124 % Fair value of warrant $ 0.0156 $ 0.0508
Schedule of Weighted Average Number of Shares [Table Text Block]	Three Months Ended Six Months Ended 2015 2014 2015 2014 $ $ $ $ Numerator: Net income (loss) available to common shareholders $ (2 ) $ 288 $ (1,102 ) $ (1,235 ) Denominator: Weighted average number of common shares outstanding - basic 9,889,028 7,944,235 9,832,274 7,912,580 Weighted average effect of dilutive securities: RSUs - 72,896 - - Stock options - 6,044 - - Weighted average number of common shares outstanding - diluted 9,889,028 8,023,175 9,832,274 7,912,580

Note 12 - Segmented Informati25

Note 12 - Segmented Information (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Three Months Ended Six Months Ended 2015 2014 2015 2014 $ $ $ $ China 2,545 1,882 4,923 3,407 United States 432 521 686 731 Europe 204 284 404 712 Asia (excluding China) 127 127 279 282 Canada 17 6 24 10 Other 238 257 518 494 Total 3,563 3,077 6,834 5,636
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended Six Months Ended 2015 2014 2015 2014 $ $ $ $ Cardiovascular 3,143 2,609 6,232 5,047 Infectious Diseases 1 3 50 72 Biodefense products 144 131 199 175 West Nile Virus (Environmental) 275 334 353 342 Total 3,563 3,077 6,834 5,636

Note 2 - Basis of Presentatio26

Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) $ in Thousands	Feb. 11, 2014USD ($)	Jun. 30, 2015CAD	Jun. 30, 2014CAD	Jun. 30, 2015CAD	Jun. 30, 2014CAD	Mar. 31, 2016USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2014CAD	Feb. 16, 2020USD ($)	Dec. 15, 2014USD ($)	Dec. 31, 2013CAD
Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) [Line Items]
Net Income (Loss) Attributable to Parent		CAD (2,000)	CAD 288,000	CAD (1,102,000)	CAD (1,235,000)			CAD (2,090,000)
Net Cash Provided by (Used in) Operating Activities				(863,000)	(1,526,000)
Cash and Cash Equivalents, at Carrying Value		1,586,000	CAD 2,611,000	1,586,000	CAD 2,611,000			3,221,000			CAD 2,958,000
Retained Earnings (Accumulated Deficit)		(121,361,000)		(121,361,000)				(120,259,000)
Stockholders' Equity Attributable to Parent		(1,776,000)		(1,776,000)				(894,000)			CAD (1,482,000)
Working Capital Deficit		2,200,000		2,200,000
Derivative Liability, Current		1,344,000		1,344,000				CAD 1,249,000
Working Capital if Excluding Warrant Liability		819,000		819,000
Warrant [Member]
Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) [Line Items]
Derivative Liability, Current		CAD 1,300,000		CAD 1,300,000
Hangzhou Joinstar Biomedical Co. Ltd. [Member]
Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) [Line Items]
Cash Proceeds from Technology Development Agreement (in Dollars) | $							$ 1,640
Development Milestone Payments [Member] | Hangzhou Joinstar Biomedical Co. Ltd. [Member] | Scenario, Forecast [Member]
Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) [Line Items]
Revenue Recognition, Milestone Method, Eligible to Receive (in Dollars) | $						$ 2,160
Revenue Based Payments [Member] | Hangzhou Joinstar Biomedical Co. Ltd. [Member]
Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) [Line Items]
Commercialization Period									5 years
Revenue Based Payments [Member] | Hangzhou Joinstar Biomedical Co. Ltd. [Member] | Scenario, Forecast [Member]
Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) [Line Items]
Cash Proceeds from Technology Development Agreement (in Dollars) | $									$ 1,780
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) [Line Items]
Concentration Risk, Percentage				70.00%
Silicon Valley Bank [Member]
Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) [Line Items]
Term Loan, Maximum Borrowing Capacity (in Dollars) | $	$ 2,500
Proceeds from Bank Debt (in Dollars) | $	$ 1,500
Debt Instrument, Face Amount (in Dollars) | $										$ 1,400
Final Payment, Percentage of Principal										4.00%

Note 4 - Fair Value Measureme27

Note 4 - Fair Value Measurements (Details) - CAD	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Note 4 - Fair Value Measurements (Details) [Line Items]
Fair Value Inputs, Discount Rate	11.00%
Derivative Liability, Current	CAD 1,344,000	CAD 1,249,000
Increase (Decrease) in Stock Price Volatility	5.00%
Warrant [Member]
Note 4 - Fair Value Measurements (Details) [Line Items]
Derivative Liability, Current	CAD 1,300,000
Pro Forma [Member] | Warrant [Member]
Note 4 - Fair Value Measurements (Details) [Line Items]
Fair Value Measurement, Liability, Impact of 5 Percent Change in Volatility	CAD 90,000	CAD 82,000

Note 4 - Fair Value Measureme28

Note 4 - Fair Value Measurements (Details) - Financial Instrument Carried at Fair Value - CAD CAD in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrant Liability	CAD 1,344	CAD 1,249
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrant Liability	CAD 1,344

Note 4 - Fair Value Measureme29

Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities - CAD CAD in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]
Warrant Liability			CAD 1,249
Warrant Liability	CAD 150	CAD (1,039)	95	CAD (878)
Warrant Liability	1,344		1,344
Fair Value, Inputs, Level 3 [Member]
Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]
Warrant Liability	1,344		1,344
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]
Warrant Liability			1,249
Warrant Liability			95
Warrant Liability	CAD 1,344		CAD 1,344

Note 4 - Fair Value Measureme30

Note 4 - Fair Value Measurements (Details) - Quantitative Information about Unobservable Inputs - Warrant [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Warrant Liability	Option Model
Warrant Liability	100.00%	106.00%

Note 5 - Inventories (Details)

Note 5 - Inventories (Details) - CAD	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Note 5 - Inventories (Details) [Line Items]
Inventory Write-down	CAD 47,000	CAD 57,000	CAD 128,000	CAD 122,000
Expired and Damaged [Member]
Note 5 - Inventories (Details) [Line Items]
Inventory Valuation Reserves	CAD 95,000		CAD 95,000		CAD 135,000

Note 5 - Inventories (Details)

Note 5 - Inventories (Details) - Inventory - CAD CAD in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventory [Abstract]
Raw materials	CAD 1,426	CAD 1,212
Work in progress	742	309
Finished goods	557	535
	CAD 2,725	CAD 2,056

Note 6 - Accounts Payable and33

Note 6 - Accounts Payable and Accrued Liabilities (Details)	Jun. 30, 2015CAD
Additions to PPE [Member]
Note 6 - Accounts Payable and Accrued Liabilities (Details) [Line Items]
Accrued Liabilities and Other Liabilities	CAD 68,000

Note 6 - Accounts Payable and34

Note 6 - Accounts Payable and Accrued Liabilities (Details) - Accounts Payable and Accrued Liabilities - CAD CAD in Thousands	Jun. 30, 2015	Dec. 31, 2014
Accounts Payable and Accrued Liabilities [Abstract]
Trade accounts payable	CAD 2,187	CAD 1,624
Employee related accounts payable and accrued liabilities	1,221	1,307
Royalties	287	287
Other accrued liabilities	1,416	649
	CAD 5,111	CAD 3,867

Note 7 - Term Loan (Details)

Note 7 - Term Loan (Details) CAD / shares in Units, $ in Millions	Feb. 11, 2014USD ($)	Jun. 30, 2015CAD	Jun. 30, 2014CAD	Jun. 30, 2015CAD	Jun. 30, 2014CAD	Dec. 15, 2014CADCAD / sharesshares	Dec. 15, 2014USD ($)
Note 7 - Term Loan (Details) [Line Items]
Amortization of Financing Costs			CAD 29,000	CAD 49,000	CAD 42,000
Amortization of Debt Discount (Premium)		CAD 14,000	CAD 9,000	29,000	CAD 14,000
Silicon Valley Bank [Member]
Note 7 - Term Loan (Details) [Line Items]
Term Loan, Maximum Borrowing Capacity (in Dollars) | $	$ 2.5
Debt Instrument, Periodic Payment, Number of Installments	32					26	26
Debt Instrument, Face Amount (in Dollars) | $							$ 1.4
Final Payment, Percentage of Principal						4.00%	4.00%
Deferred Finance Costs, Net						CAD 233,000
Amortization of Financing Costs		CAD 24,000		CAD 50,000
Silicon Valley Bank [Member] | Prime Rate [Member]
Note 7 - Term Loan (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.50%
Silicon Valley Bank [Member]
Note 7 - Term Loan (Details) [Line Items]
Class of Warrant or Right, Issued During Period (in Shares) | shares						107,701
Fair Value Assumptions, Expected Term						10 years
Fair Value of Warrant						CAD 113,000
Minimum [Member] | Silicon Valley Bank [Member]
Note 7 - Term Loan (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | CAD / shares						CAD 1
Maximum [Member] | Silicon Valley Bank [Member]
Note 7 - Term Loan (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | CAD / shares						CAD 1.831

Note 7 - Term Loan (Details) -

Note 7 - Term Loan (Details) - Term Loan Componnets - CAD CAD in Thousands	Jun. 30, 2015	Dec. 31, 2014
Term Loan Componnets [Abstract]
Current portion of term loan	CAD 783	CAD 546
Current portion of unamortized debt discount	(39)	(52)
Current portion of long-term debt, net debt discount	744	494
Long-term portion of term loan	717	1,031
Long-term portion of unamortized debt discount	(11)	(27)
Long-term of long-term debt, net debt discount	706	1,004
Total	CAD 1,450	CAD 1,498

Note 7 - Term Loan (Details) 37

Note 7 - Term Loan (Details) - Future Principal Payments for Term Loan (Incomplete) - Term Loan [Member] CAD in Thousands	Jun. 30, 2015CAD
Note 7 - Term Loan (Details) - Future Principal Payments for Term Loan (Incomplete) [Line Items]
2,016	CAD 783
2,017	717
Total	CAD 1,500

Note 8 - Lease Inducements (Det

Note 8 - Lease Inducements (Details) - CAD	Apr. 01, 2008	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Note 8 - Lease Inducements (Details) [Line Items]
Interest Expense		CAD 225,000	CAD 226,000	CAD 460,000	CAD 423,000
Lease Incentive One [Member]
Note 8 - Lease Inducements (Details) [Line Items]
Amortization of Lease Incentives, Lessee		13,000	13,000	27,000	27,000
Lease Incentive Two [Member]
Note 8 - Lease Inducements (Details) [Line Items]
Amortization of Lease Incentives, Lessee		29,000	28,000	58,000	57,000
Allowance for Leasehold Improvement, Non-repayable	CAD 1,700,000
Lease Incentive Three [Member]
Note 8 - Lease Inducements (Details) [Line Items]
Amortization of Lease Incentives, Lessee		114,000	102,000	224,000	201,000
Allowance for Leasehold Improvement, Repayable	7,800,000
Interest Expense		152,000	CAD 164,000	307,000	CAD 330,000
Lease Incentive Three [Member] | Monthly [Member]
Note 8 - Lease Inducements (Details) [Line Items]
Allowance for Leasehold Improvement, Repayable	CAD 89,000
Letter of Credit [Member]
Note 8 - Lease Inducements (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		CAD 871,000		CAD 871,000
Line of Credit Facility, Collateral	$ 871,000

Note 8 - Lease Inducements (D39

Note 8 - Lease Inducements (Details) - Summary of Lease Inducements - CAD CAD in Thousands		Jun. 30, 2015	Dec. 31, 2014
Current Portion
Lease Incentive Payable, Current		CAD 169	CAD 169
Repayable leasehold improvement allowance [iii]	[1]	487	461
Total Current Portion		656	630
Long-Term Portion
Lease Incentive Payable, Noncurrent		1,112	1,197
Repayable leasehold improvement allowance [iii]	[1]	4,958	5,208
Total Long-Term Portion		6,070	6,405
Total		6,726	7,035
Rent-free Inducement [Member]
Current Portion
Lease Incentive Payable, Current	[2]	55	54
Long-Term Portion
Lease Incentive Payable, Noncurrent	[2]	357	385
Repayable Leasehold Improvement Allowance [Member]
Current Portion
Lease Incentive Payable, Current	[3]	114	115
Long-Term Portion
Lease Incentive Payable, Noncurrent	[3]	CAD 755	CAD 812
[1]	The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three and six month periods ended June 30, 2015 amounted to $114,000 and $224,000 [2014 - $102,000 and $201,000]. Interest payments for the three and six month periods ended June 30, 2015 amounted to $152,000 and $307,000 [2014 - $164,000 and $330,000].
[2]	In 2007, the Company entered into a long-term facility lease agreement that included an eight and one half month rent-free period from May 17, 2007 to February 1, 2008. The lease inducement benefit arising from the rent-free period is being amortized on a straight-line basis over the term of the operating lease as a reduction to rental expense. Amortization expense for the three and six month periods ended June 30, 2015 amounted to $13,000 and $27,000 [2014 - $13,000 and $27,000].
[3]	The Company received a non-repayable allowance for an amount of $1.7 million for expenditures related to general upgrades to the facility. The lease inducement benefit arising from the non-repayable leasehold improvement allowance is being amortized on a straight-line basis over the balance of the term of the lease beginning April 1, 2008 as a reduction to rental expense. Amortization expense for the three and six month periods ended June 30, 2015 amounted to $29,000 and $58,000 [2014 - $28,000 and $57,000].

Note 9 - Share Capital and Ad40

Note 9 - Share Capital and Additional Paid-in Capital (Details) - CAD	Dec. 12, 2014	Jun. 18, 2013	Jun. 08, 2013	Sep. 03, 2008	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					1,333,835		1,333,835		1,007,629
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)					CAD 634,000		CAD 634,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							2 years 135 days
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					0		0
Restricted Stock Units (RSUs) [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					248,131		248,131
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					135,642		135,642
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			1
Deferred Share Unit Plan (DSUs) [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					248,131		248,131
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					248,131		248,131
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		1
Hangzhou Joinstar Biomedical Co. Ltd. [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Proceeds from Issuance of Private Placement (in Dollars)	CAD 2,024,000
Payments of Financing Costs (in Dollars)	CAD 154,000
Hangzhou Joinstar Biomedical Co. Ltd. [Member] | Private Placement [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	1,800,000
Sale of Stock, Price Per Share (in Dollars per share)	CAD 1.21
Stock Issued During Period Value Private Placement, Gross (in Dollars)	CAD 2,178,000
Accounts Payable and Accrued Liabilities [Member] | Restricted Stock Units (RSUs) [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Stock Issued During Period, Value, Issued for Services (in Dollars)							CAD 115,000
Warrant [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount					86,865,691	86,810,786	86,865,691	86,810,786
Employee Stock Option [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount					1,333,835		1,333,835	1,455,362
Restricted Stock Units (RSUs) [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount					112,489	1,422,632	112,489	72,896
Common Stock [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding					86,865,691		86,865,691
Common Stock [Member] | Private Placement [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Stock Issued During Period, Shares, New Issues									1,800,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					1		1
Stock Option Plan 2008 [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Percentage of Shares					20.00%		20.00%
Stock Option Plan 2008 [Member] | Employee Stock Option [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					1,985,051		1,985,051
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					1,333,835		1,333,835
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					651,216		651,216
Private Placement [Member] | Common Stock [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding					636,557		636,557
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					CAD 3.58		CAD 3.58
Private Placement [Member] | Warrant [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					CAD 1.461		CAD 1.461
Related to 2011 Financing [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding					86,103,744		86,103,744
Agent Warrants [Member] | Common Stock [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding					17,689		17,689
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					CAD 2.45		CAD 2.45
Silicon Valley Bank [Member] | Warrant [Member] | Common Share Price $1.83 [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding					52,796		52,796
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					CAD 1.831		CAD 1.831
Silicon Valley Bank [Member] | Warrant [Member] | Common Share Price 1.00 [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding					54,905		54,905
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					CAD 1		CAD 1

Note 9 - Share Capital and Ad41

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Share-based Payment Award, Stock Options, Valuation Assumptions - CAD / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]
Risk-free interest rates	1.31%	2.05%
Expected dividend yield	0.00%	0.00%
Expected life (in years)	5 years 284 days	5 years 313 days
Expected volatility	121.00%	126.00%
Fair value per stock option (in Dollars per share)	CAD 0.67	CAD 1.31

Note 9 - Share Capital and Ad42

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding - Jun. 30, 2015 - CAD / shares	Total
Range One [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	CAD 0.72
Range of exercise price- upper	CAD 0.92
Number of shares under option (in Shares)	519,433
Weighted average remaining contractual life	9 years 284 days
Weighted average exercise price	CAD 0.79
Range Two [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	1.02
Range of exercise price- upper	CAD 1.60
Number of shares under option (in Shares)	259,592
Weighted average remaining contractual life	8 years 10 days
Weighted average exercise price	CAD 1.48
Number of options currently exercisable (in Shares)	160,388
Weighted average exercise price - exercisable	CAD 1.45
Range Three [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- upper	CAD 2.20
Number of shares under option (in Shares)	386,361
Weighted average remaining contractual life	6 years 288 days
Weighted average exercise price	CAD 2.20
Number of options currently exercisable (in Shares)	361,414
Weighted average exercise price - exercisable	CAD 2.20
Range Four [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	3
Range of exercise price- upper	CAD 3.10
Number of shares under option (in Shares)	166,625
Weighted average remaining contractual life	7 years 262 days
Weighted average exercise price	CAD 3.09
Number of options currently exercisable (in Shares)	154,422
Weighted average exercise price - exercisable	CAD 3.10
Range Five [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	6.80
Range of exercise price- upper	CAD 8.20
Number of shares under option (in Shares)	1,824
Weighted average remaining contractual life	226 days
Weighted average exercise price	CAD 7.70
Number of options currently exercisable (in Shares)	1,824
Weighted average exercise price - exercisable	CAD 7.70
Range Six [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	0.72
Range of exercise price- upper	CAD 8.20
Number of shares under option (in Shares)	1,333,835
Weighted average remaining contractual life	8 years 109 days
Weighted average exercise price	CAD 1.63
Number of options currently exercisable (in Shares)	678,048
Weighted average exercise price - exercisable	CAD 2.24

Note 9 - Share Capital and Ad43

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Activity - 6 months ended Jun. 30, 2015 - $ / shares	Total
Stock Options, Activity [Abstract]
Balance	1,333,835
Balance	$ 1.63
Options granted	449,743
Options granted	$ 0.78
Options forfeited	(123,537)
Options forfeited	$ 1.47

Note 9 - Share Capital and Ad44

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan - 6 months ended Jun. 30, 2015 - Restricted Stock Units (RSUs) [Member] - CAD / shares	Total
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan [Line Items]
Balance	112,489
Balance	CAD 1.02
RSUs granted	141,837
RSUs granted	CAD 0.81
RSUs converted to common shares	(165,696)
RSUs converted to common shares	CAD (1.15)

Note 9 - Share Capital and Ad45

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Allocation of Stock-based Compensation, by Type of Cost - CAD CAD in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	CAD 50	CAD 82	CAD 105	CAD 233
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	9	9	17	18
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	11	11	22	23
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	27	50	50	169
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	CAD 3	CAD 12	CAD 16	CAD 23

Note 9 - Share Capital and Ad46

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Estimated Fair Value of Warrants Issued - Warrant [Member] - CAD	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Estimated Fair Value of Warrants Issued [Line Items]
Risk-free interest rates	0.49%	1.09%
Expected dividend yield	0.00%	0.00%
Expected life (in years)	1 year 6 months	2 years 6 months
Expected volatility	100.00%	124.00%
Fair value of warrant (in Dollars)	CAD 0.0156	CAD 0.0508

Note 9 - Share Capital and Ad47

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Reconciliation of Weighted Average Number of Common Shares Outstanding - CAD shares in Thousands, CAD in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Numerator:
Net income (loss) available to common shareholders (in Dollars)	CAD (2)	CAD 288	CAD (1,102)	CAD (1,235)	CAD (2,090)
Denominator:
Weighted average number of common shares outstanding - basic	9,889,028	7,944,235	9,832,274	7,912,580
Weighted average effect of dilutive securities:
Weighted average number of common shares outstanding - diluted	9,889,028	8,023,175	9,832,274	7,912,580
Restricted Stock Units (RSUs) [Member]
Weighted average effect of dilutive securities:
Weighted average effect of dilutive securities		72,896
Employee Stock Option [Member]
Weighted average effect of dilutive securities:
Weighted average effect of dilutive securities		6,044

Note 10 - Related Party Trans48

Note 10 - Related Party Transactions (Details) $ in Thousands	Oct. 22, 2014CAD	Jun. 30, 2015CAD	Jun. 30, 2015CAD	Jun. 30, 2015USD ($)
Note 10 - Related Party Transactions (Details) [Line Items]
Contracts Revenue		CAD 703,000	CAD 972,000
Hangzhou Joinstar Biomedical Co. Ltd. [Member]
Note 10 - Related Party Transactions (Details) [Line Items]
Cash Proceeds from Technology Development Agreement | $				$ 1,640
Hangzhou Joinstar Biomedical Co. Ltd. [Member] | Upfront Payment [Member]
Note 10 - Related Party Transactions (Details) [Line Items]
Cash Proceeds from Technology Development Agreement	CAD 1,280,000
Contracts Revenue		246,000	515,000
Hangzhou Joinstar Biomedical Co. Ltd. [Member] | Milestone Payments [Member]
Note 10 - Related Party Transactions (Details) [Line Items]
Cash Proceeds from Technology Development Agreement		360,000
Hangzhou Joinstar Biomedical Co. Ltd. [Member] | Collaborative Revenue [Member] | Milestone Payments [Member]
Note 10 - Related Party Transactions (Details) [Line Items]
Contracts Revenue		CAD 457,000	CAD 457,000

Note 11 - Commitments (Details)

Note 11 - Commitments (Details)	1 Months Ended	3 Months Ended		6 Months Ended		24 Months Ended
	Sep. 30, 2003	Jun. 30, 2015CADft²	Jun. 30, 2014CAD	Jun. 30, 2015CADft²	Jun. 30, 2014CAD	Jun. 30, 2007CAD
Note 11 - Commitments (Details) [Line Items]
Royalty Expense						CAD 2,000,000
Royalty Expense, Percentage of Revenue	10.00%
Operating Leases, Rent Expense, Net		CAD 211,000	CAD 203,000	CAD 406,000	CAD 389,000
Purchase Obligation		3,000,000		3,000,000
Purchase Obligation, Future Minimum Payments, Remainder of Fiscal Year		CAD 2,000,000		CAD 2,000,000
Operation Facility [Member]
Note 11 - Commitments (Details) [Line Items]
Area of Real Estate Property (in Square Feet) | ft²		46,000		46,000
Operating Lease, Monthly Payments				CAD 173,000
Office in China [Member]
Note 11 - Commitments (Details) [Line Items]
Operating Lease, Monthly Payments				8,000
West Nile Virus [Member]
Note 11 - Commitments (Details) [Line Items]
Royalty Expense		CAD 27,000	31,000	35,000	31,000
Developed Technology Rights [Member]
Note 11 - Commitments (Details) [Line Items]
Royalty Expense		CAD 248,000	CAD 157,000	CAD 465,000	CAD 274,000

Note 12 - Segmented Informati50

Note 12 - Segmented Information (Details) - CAD CAD in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage			70.00%
One Customer [Member]
Note 12 - Segmented Information (Details) [Line Items]
Revenues (in Dollars)	CAD 2.5		CAD 4.8
One Customer [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage			71.00%
Three Customers [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage	70.00%
Four Customers [Member]
Note 12 - Segmented Information (Details) [Line Items]
Revenues (in Dollars)		CAD 2.2		CAD 4
Four Customers [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage		72.00%		71.00%
Customer One [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage		23.00%		29.00%
Customer Two and Three [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage		19.00%
Customer Four [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage		11.00%		10.00%
Customer Two [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage				21.00%
Customer Three [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage				11.00%

Note 12 - Segmented Informati51

Note 12 - Segmented Information (Details) - Product Sales by Customer Location - CAD CAD in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	CAD 3,563	CAD 3,077	CAD 6,834	CAD 5,636
CHINA
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	2,545	1,882	4,923	3,407
UNITED STATES
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	432	521	686	731
Europe [Member]
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	204	284	404	712
Asia (excluding China) [Member]
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	127	127	279	282
CANADA
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	17	6	24	10
Segment, Geographical, Groups of Countries, Group Three [Member]
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	CAD 238	CAD 257	CAD 518	CAD 494

Note 12 - Segmented Informati52

Note 12 - Segmented Information (Details) - Product Sales by Type of Product - CAD CAD in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Product sales	CAD 3,563	CAD 3,077	CAD 6,834	CAD 5,636
Cardiovascular [Member]
Segment Reporting Information [Line Items]
Product sales	3,143	2,609	6,232	5,047
Infectious Diseases [Member]
Segment Reporting Information [Line Items]
Product sales	1	3	50	72
Bio-defense Products [Member]
Segment Reporting Information [Line Items]
Product sales	144	131	199	175
West Nile Virus [Member]
Segment Reporting Information [Line Items]
Product sales	CAD 275	CAD 334	CAD 353	CAD 342

Uncategorized Items - rpbif-201

Label	Element	Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	$ 1.99
Restricted Stock Units (RSUs) [Member]
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	rpbif_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	$ 1.39
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	136,348